[1]
Lieberman JR,Bell JA, Venous Thromboembolic Prophylaxis After Total Hip and Knee Arthroplasty. The Journal of bone and joint surgery. American volume. 2021 Aug 18
[PubMed PMID: 34133395]
[2]
Segon YS,Summey RD,Slawski B,Kaatz S, Surgical venous thromboembolism prophylaxis: clinical practice update. Hospital practice (1995). 2020 Dec
[PubMed PMID: 32589468]
[3]
Benes J,Skulec R,Jobanek J,Cerny V, Fixed-dose enoxaparin provides efficient DVT prophylaxis in mixed ICU patients despite low anti-Xa levels: A prospective observational cohort study. Biomedical papers of the Medical Faculty of the University Palacky, Olomouc, Czechoslovakia. 2022 May
[PubMed PMID: 34042098]
[4]
Schomburg J, Krishna S, Soubra A, Cotter K, Fan Y, Brown G, Konety B. Extended outpatient chemoprophylaxis reduces venous thromboembolism after radical cystectomy. Urologic oncology. 2018 Feb:36(2):77.e9-77.e13. doi: 10.1016/j.urolonc.2017.09.029. Epub 2017 Oct 31
[PubMed PMID: 29097086]
[5]
Collet JP,Thiele H,Barbato E,Barthélémy O,Bauersachs J,Bhatt DL,Dendale P,Dorobantu M,Edvardsen T,Folliguet T,Gale CP,Gilard M,Jobs A,Jüni P,Lambrinou E,Lewis BS,Mehilli J,Meliga E,Merkely B,Mueller C,Roffi M,Rutten FH,Sibbing D,Siontis GCM,ESC Scientific Document Group., 2020 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. European heart journal. 2021 Apr 7
[PubMed PMID: 32860058]
[6]
van Gameren M,Lemmert ME,Wilschut JM,Daemen J,De Jaegere PPT,Zijlstra F,Van Mieghem NMDA,Diletti R, An update on the use of anticoagulant therapy in ST-segment elevation myocardial infarction. Expert opinion on pharmacotherapy. 2018 Sep;
[PubMed PMID: 30185087]
Level 3 (low-level) evidence
[7]
American College of Obstetricians and Gynecologists' Committee on Practice Bulletins—Obstetrics. ACOG Practice Bulletin No. 196: Thromboembolism in Pregnancy. Obstetrics and gynecology. 2018 Jul:132(1):e1-e17. doi: 10.1097/AOG.0000000000002706. Epub
[PubMed PMID: 29939938]
[8]
Douketis JD,Spyropoulos AC,Spencer FA,Mayr M,Jaffer AK,Eckman MH,Dunn AS,Kunz R, Perioperative management of antithrombotic therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012 Feb;
[PubMed PMID: 22315266]
Level 1 (high-level) evidence
[9]
Xing J,Yin X,Chen D, Rivaroxaban versus enoxaparin for the prevention of recurrent venous thromboembolism in patients with cancer: A meta-analysis. Medicine. 2018 Aug;
[PubMed PMID: 30075504]
Level 1 (high-level) evidence
[10]
Nutescu EA,Burnett A,Fanikos J,Spinler S,Wittkowsky A, Pharmacology of anticoagulants used in the treatment of venous thromboembolism. Journal of thrombosis and thrombolysis. 2016 Jan;
[PubMed PMID: 26780737]
[11]
Febbraro S,Leal Martínez-Bujanda J,Nieto Magro C,Bettica P, Bioavailability study of Enoxaparin Sodium Chemi (80 mg/0.8 mL) and Clexane (80 mg/0.8 mL) subcutaneous injection in healthy adults. International journal of clinical pharmacology and therapeutics. 2021 Nov
[PubMed PMID: 34402789]
[13]
Kahn SR, Lim W, Dunn AS, Cushman M, Dentali F, Akl EA, Cook DJ, Balekian AA, Klein RC, Le H, Schulman S, Murad MH. Prevention of VTE in nonsurgical patients: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012 Feb:141(2 Suppl):e195S-e226S. doi: 10.1378/chest.11-2296. Epub
[PubMed PMID: 22315261]
Level 1 (high-level) evidence
[14]
Streiff MB,Agnelli G,Connors JM,Crowther M,Eichinger S,Lopes R,McBane RD,Moll S,Ansell J, Guidance for the treatment of deep vein thrombosis and pulmonary embolism. Journal of thrombosis and thrombolysis. 2016 Jan
[PubMed PMID: 26780738]
[15]
Rivera-Lebron B,McDaniel M,Ahrar K,Alrifai A,Dudzinski DM,Fanola C,Blais D,Janicke D,Melamed R,Mohrien K,Rozycki E,Ross CB,Klein AJ,Rali P,Teman NR,Yarboro L,Ichinose E,Sharma AM,Bartos JA,Elder M,Keeling B,Palevsky H,Naydenov S,Sen P,Amoroso N,Rodriguez-Lopez JM,Davis GA,Rosovsky R,Rosenfield K,Kabrhel C,Horowitz J,Giri JS,Tapson V,Channick R,PERT Consortium., Diagnosis, Treatment and Follow Up of Acute Pulmonary Embolism: Consensus Practice from the PERT Consortium. Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis. 2019 Jan-Dec;
[PubMed PMID: 31185730]
Level 3 (low-level) evidence
[16]
O'Gara PT, Kushner FG, Ascheim DD, Casey DE Jr, Chung MK, de Lemos JA, Ettinger SM, Fang JC, Fesmire FM, Franklin BA, Granger CB, Krumholz HM, Linderbaum JA, Morrow DA, Newby LK, Ornato JP, Ou N, Radford MJ, Tamis-Holland JE, Tommaso CL, Tracy CM, Woo YJ, Zhao DX, Anderson JL, Jacobs AK, Halperin JL, Albert NM, Brindis RG, Creager MA, DeMets D, Guyton RA, Hochman JS, Kovacs RJ, Kushner FG, Ohman EM, Stevenson WG, Yancy CW, American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation. 2013 Jan 29:127(4):e362-425. doi: 10.1161/CIR.0b013e3182742cf6. Epub 2012 Dec 17
[PubMed PMID: 23247304]
Level 3 (low-level) evidence
[17]
Amsterdam EA, Wenger NK, Brindis RG, Casey DE Jr, Ganiats TG, Holmes DR Jr, Jaffe AS, Jneid H, Kelly RF, Kontos MC, Levine GN, Liebson PR, Mukherjee D, Peterson ED, Sabatine MS, Smalling RW, Zieman SJ, ACC/AHA Task Force Members. 2014 AHA/ACC guideline for the management of patients with non-ST-elevation acute coronary syndromes: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation. 2014 Dec 23:130(25):e344-426. doi: 10.1161/CIR.0000000000000134. Epub 2014 Sep 23
[PubMed PMID: 25249585]
Level 1 (high-level) evidence
[18]
Gish RG,Flamm SL, Anticoagulation in Patients With Chronic Liver Disease. Gastroenterology & hepatology. 2021 Jan
[PubMed PMID: 34135699]
[19]
Aursulesei V,Costache II, Anticoagulation in chronic kidney disease: from guidelines to clinical practice. Clinical cardiology. 2019 Aug;
[PubMed PMID: 31102275]
[21]
Cuker A,Tseng EK,Schünemann HJ,Angchaisuksiri P,Blair C,Dane K,DeSancho MT,Diuguid D,Griffin DO,Kahn SR,Klok FA,Lee AI,Neumann I,Pai A,Righini M,Sanfilippo KM,Siegal DM,Skara M,Terrell DR,Touri K,Akl EA,Al Jabiri R,Al Jabiri Y,Boulos M,Brignardello-Petersen R,Charide R,Colunga-Lozano LE,Dearness K,Darzi AJ,Karam SG,Morgano GP,Morsi RZ,Philip BA,Benitez YR,Stevens A,Solo K,Wiercioch W,Mustafa RA,Nieuwlaat R, American Society of Hematology living guidelines on the use of anticoagulation for thromboprophylaxis for patients with COVID-19: March 2022 update on the use of anticoagulation in critically ill patients. Blood advances. 2022 Sep 13
[PubMed PMID: 35748885]
Level 3 (low-level) evidence
[23]
Agarwal S,Lamani YP,Goudar BV,Kalburgi EB,Bhavi BK, Rectus Sheath Haematoma Secondary to Enoxaparin Injection- A Rare Case Report. Journal of clinical and diagnostic research : JCDR. 2017 Mar;
[PubMed PMID: 28511448]
Level 3 (low-level) evidence
[24]
Ozdemir D,Tam AA,Dirikoc A,Ersoy R,Cakir B, Postpartum osteoporosis and vertebral fractures in two patients treated with enoxaparin during pregnancy. Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA. 2015 Jan
[PubMed PMID: 25138263]
[25]
Low Molecular Weight Heparins LiverTox: Clinical and Research Information on Drug-Induced Liver Injury. 2012
[PubMed PMID: 31643341]
[26]
Uceda-Martin M,Lambert A,Miremont G,Gaiffe A,Agier MS,Studer M,Mahé A,Tebacher M,Cribier B, Bullous haemorrhagic dermatitis induced by heparins and other anticoagulants: 94 cases from French pharmacovigilance centres and a literature review. Annales de dermatologie et de venereologie. 2022 Mar
[PubMed PMID: 34175142]
Level 3 (low-level) evidence
[27]
Leguísamo S,Prados Castaño M,Piñero Saavedra M,Cimbollek S, Recurrent Anaphylaxis Due to Enoxaparin. Journal of investigational allergology
[PubMed PMID: 26310046]
[28]
Singla A,Amini MR,Alpert MA,Gornik HL, Fatal anaphylactoid reaction associated with heparin-induced thrombocytopenia. Vascular medicine (London, England). 2013 Jun;
[PubMed PMID: 23579400]
[29]
Barcellona D,Melis M,Floris G,Mameli A,Muroni A,Defazio G,Marongiu F, A "Catastrophic" Heparin-Induced Thrombocytopenia. Case reports in medicine. 2020
[PubMed PMID: 32328108]
Level 3 (low-level) evidence
[30]
Sridharan K,Hasan HM,Al Jufairi M,Al Daylami A,Al Ansari E,Qader AM,Pasha SAA, Possible effects of excipients used in the parenteral drugs administered in critically ill adults, children, and neonates. Expert opinion on drug safety. 2020 Dec
[PubMed PMID: 32767900]
Level 3 (low-level) evidence
[31]
Al-Taee AM,Ghoulam E,Lee P,Edwards M,Mohammed KA,Hachem CY, Underutilization of Peptic Ulcer Disease Prophylaxis Among Elderly Users of Antiplatelets and Anticoagulants. Digestive diseases and sciences. 2021 Oct
[PubMed PMID: 33085015]
[32]
Tang N,Chen S,Shi X,Ye Z,Zheng X, Effect of enoxaparin on clinical events after percutaneous coronary intervention. International journal of clinical and experimental medicine. 2015;
[PubMed PMID: 26379875]
[33]
Ayad SW,Hassanein MM,Mohamed EA,Gohar AM, Maternal and Fetal Outcomes in Pregnant Women with a Prosthetic Mechanical Heart Valve. Clinical Medicine Insights. Cardiology. 2016
[PubMed PMID: 26884686]
[34]
Shehab N,Lovegrove MC,Geller AI,Rose KO,Weidle NJ,Budnitz DS, US Emergency Department Visits for Outpatient Adverse Drug Events, 2013-2014. JAMA. 2016 Nov 22;
[PubMed PMID: 27893129]
[35]
Tran VN,Varfolomeev I,Hill G, Prophylactic Enoxaparin Dosing in Obese Orthopedic Patients: A Literature Search. Hospital pharmacy. 2020 Dec
[PubMed PMID: 33245721]
[36]
Dybdahl D,Walliser G,Pershing M,Collins C,Robinson D, Enoxaparin Dosing for Venous Thromboembolism Prophylaxis in Low Body Weight Patients. Clinical medicine insights. Blood disorders. 2019
[PubMed PMID: 31360075]
[37]
Miranda S,Le Cam-Duchez V,Benichou J,Donnadieu N,Barbay V,Le Besnerais M,Delmas FX,Cuvelier A,Lévesque H,Benhamou Y,Armengol G, Adjusted value of thromboprophylaxis in hospitalized obese patients: A comparative study of two regimens of enoxaparin: The ITOHENOX study. Thrombosis research. 2017 Jul;
[PubMed PMID: 28460259]
Level 2 (mid-level) evidence
[38]
Rosencher N,Llau JV,Mueck W,Loewe A,Berkowitz SD,Homering M, Incidence of neuraxial haematoma after total hip or knee surgery: RECORD programme (rivaroxaban vs. enoxaparin). Acta anaesthesiologica Scandinavica. 2013 May;
[PubMed PMID: 23336294]
[39]
McCarty D,Robinson A, Factor Xa inhibitors: a novel therapeutic class for the treatment of nonvalvular atrial fibrillation. Therapeutic advances in cardiovascular disease. 2016 Feb;
[PubMed PMID: 26378211]
Level 3 (low-level) evidence
[40]
Seidel R,Tietke M,Heese O,Walter U, Serious Complications After Epidural Catheter Placement: Two Case Reports. Local and regional anesthesia. 2021;
[PubMed PMID: 34335056]
Level 3 (low-level) evidence
[42]
Tahaineh L,Edaily SM,Gharaibeh SF, Anti-factor Xa levels in obese patients receiving enoxaparin for treatment and prophylaxis indications. Clinical pharmacology : advances and applications. 2018;
[PubMed PMID: 29849468]
Level 3 (low-level) evidence
[43]
Garcia DA, Baglin TP, Weitz JI, Samama MM. Parenteral anticoagulants: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012 Feb:141(2 Suppl):e24S-e43S. doi: 10.1378/chest.11-2291. Epub
[PubMed PMID: 22315264]
Level 1 (high-level) evidence
[44]
Ahuja T,Mousavi KM,Klejmont L,Desai S, Enoxaparin Dosing and AntiXa Monitoring in Specialty Populations: A Case Series of Renal-Impaired, Extremes of Body Weight, Pregnant, and Pediatric Patients. P
[PubMed PMID: 30271105]
Level 2 (mid-level) evidence
[45]
Yamamoto S,Sakakura K,Taniguchi Y,Yamamoto K,Wada H,Momomura SI,Fujita H, Safety of Reversing Anticoagulation by Protamine Following Elective Transfemoral Percutaneous Coronary Intervention in the Drug-Eluting Stent Era. International heart journal. 2018 May 30;
[PubMed PMID: 29743410]
[46]
Kalathottukaren MT,Creagh AL,Abbina S,Lu G,Karbarz MJ,Pandey A,Conley PB,Kizhakkedathu JN,Haynes C, Comparison of reversal activity and mechanism of action of UHRA, andexanet, and PER977 on heparin and oral FXa inhibitors. Blood advances. 2018 Aug 28
[PubMed PMID: 30135185]
Level 3 (low-level) evidence
[47]
Vatanparast R,Lantz S,Ward K,Crilley PA,Styler M, Evaluation of a pretest scoring system (4Ts) for the diagnosis of heparin-induced thrombocytopenia in a university hospital setting. Postgraduate medicine. 2012 Nov
[PubMed PMID: 23322137]
[48]
Warkentin TE,Smythe MA,Ali MA,Aslam N,Sheppard JI,Smith JW,Moore JC,Arnold DM,Nazy I, Serotonin-release assay-positive but platelet factor 4-dependent enzyme-immunoassay negative: HIT or not HIT? American journal of hematology. 2021 Mar 1
[PubMed PMID: 33326124]
[49]
Colarossi G,Maffulli N,Trivellas A,Schnöring H,Hatam N,Tingart M,Migliorini F, Superior outcomes with Argatroban for heparin-induced thrombocytopenia: a Bayesian network meta-analysis. International journal of clinical pharmacy. 2021 Aug;
[PubMed PMID: 33774764]
Level 1 (high-level) evidence
[50]
Pingleton SK,Carlton E,Wilkinson S,Beasley J,King T,Wittkopp C,Moncure M,Williamson T, Reduction of venous thromboembolism (VTE) in hospitalized patients: aligning continuing education with interprofessional team-based quality improvement in an academic medical center. Academic medicine : journal of the Association of American Medical Colleges. 2013 Oct
[PubMed PMID: 23969376]
Level 2 (mid-level) evidence